knowledge -WSS

knowledge

author：focus 2025-09-06 04:38:32 - browse：1956

Scientist Nour Tabidi prepares a DNA sample in a lab. -- health coverage from STAT — Scientist Nour Tabidi prepares a DNA sample in a lab at Thermo Fisher's recently opened manufacturing plant in Plainville. John Tlumacki/Globe Staff

Thermo Fisher Scientific’s giant plant to manufacture gene therapies for drug companies is barely a year old, but executives at the maker of scientific tools are already talking about expanding.

Standing inside a cavernous unfinished section of the plant, Paul Fitzgerald, vice president and general manager of the site, told a group of biotech executives, journalists, and other visitors that he’s eager to transform it into laboratories. So far, the company is only using about 290,000 of the plant’s more than 400,000 square feet.

“I look forward to you guys giving us a reason to fill up this space,” Fitzgerald quipped during a tour Tuesday of the plant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： 3 questions for the future of Biden's cancer moonshot

focus

WSS

Bristol 'take

Changes to biosimilar regulatory framework must prioritize patients

Hearing on Medicare drug price negotiation gets unusually heated

Medical student insurance fails on mental health care coverage

What to expect at HLTH 2023, the health care industry conference

Lasker Awards 2023: Winners in biomedical research

knowledge

knowledge

focus

Anesthesiologist group: stop taking Ozempic before surgery

Colorectal cancer study finds potential in overlooked immune cell

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Stroke deaths set to near 10 million globally by 2050

How one medical school became remarkably diverse

Microbiome research is starting to find links to chronic diseases

ChatGPT in medicine: STAT answers readers' burning questions

CommonSpirit Health keeps growing, even as it loses money

The high cost of giving birth even with insurance

Intarcia’s device

hotspot

Stroke deaths set to near 10 million globally by 2050

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Why Charlie Gard's case is so disturbing to Americans

Physician executives need more than on

EpiPen alternative approval delay highlights citizen petition issue

Intarcia’s device

focus

knowledge

focus

leisure time